Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Christoph Klade"'
Autor:
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian
Publikováno v:
HemaSphere, Vol 7, p e216416f (2023)
Externí odkaz:
https://doaj.org/article/4d7243c8e5154d6eb203cf6a0a30256f
Autor:
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Viktor Rossiev, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian, for the PROUD-PV Study Group
Publikováno v:
HemaSphere, Vol 4, Iss 6, p e485 (2020)
Externí odkaz:
https://doaj.org/article/5fda375d5298471dabb1ce29d4ebc970
Autor:
Martin Unger, Andrea Morelli, Mervyn Singer, Peter Radermacher, Sebastian Rehberg, Helmut Trimmel, Michael Joannidis, Gottfried Heinz, Vladimír Cerny, Pavel Dostál, Christian Siebers, Fabio Guarracino, Francesca Pratesi, Gianni Biancofiore, Massimo Girardis, Pavla Kadlecova, Olivier Bouvet, Michael Zörer, Barbara Grohmann-Izay, Kurt Krejcy, Christoph Klade, Günther Krumpl
Publikováno v:
Trials, Vol 19, Iss 1, Pp 1-8 (2018)
Abstract Background In patients with septic shock, the presence of an elevated heart rate (HR) after fluid resuscitation marks a subgroup of patients with a particularly poor prognosis. Several studies have shown that HR control in this population is
Externí odkaz:
https://doaj.org/article/0ddf60e0acac47658fedffd750bc75eb
Autor:
Jakob Weinzierl, Martin Schalling, Michael Zörer, Kurt Krejcy, Heinz Gisslinger, Roland Jäger, Christoph Klade, Jelena D. Milosevic Feenstra, Elisabeth Fuchs, Fiorella Schischlik, Edith Bogner, Robert Kralovics, Bettina Gisslinger
Publikováno v:
Blood
Interferon-α (IFN-α)–based treatments can induce hematologic and molecular responses (HRs and MRs, respectively) in polycythemia vera (PV); however, patients do not respond equally. Germline genetic factors have been implicated in differential dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36f40663b9884d08310990bb3fcc5566
https://doi.org/10.1182/blood.2020005792
https://doi.org/10.1182/blood.2020005792
Autor:
Ella Willenbacher, Zita Borbényi, Steffen Koschmieder, Robert Kralovics, Mario Cazzola, Uwe Platzbecker, Emanuil Gheorghita, Pencho Georgiev, Heinz Gisslinger, Mathieu Puyade, Malgorzata Calbecka, Jerome Rey, Kurt Krejcy, Jiri Mayer, Krzysztof Warzocha, Emilie Cayssials-Caylus, Veronika Buxhofer-Ausch, János Jakucs, Anna Vallova, Georgi Mihaylov, Hans Carl Hasselbalch, Lydia Roy, Vera Yablokova, Olga Cerna, Aleksander Skotnicki, Richard Greil, Jiri Schwarz, Vera Stoeva, Lylia Sivcheva, Zvenyslava Masliak, Halyna Pylypenko, Antonia Hatalova, Delia Dima, Jose Miguel Torregrosa-Diaz, Elena Volodicheva, Jean-Jacques Kiladjian, S V Klymenko, Carlos Besses Raebel, Polina Kaplan, Irina Sokolova, Horia Bumbea, Miklos Egyed, Nicoleta Berbec, Barbara Grohmann-Izay, Alexander Myasnikov, Petr Dulicek, Tamila Lysa, Dominik Wolf, Andrei Cucuianu, Christoph Klade, Mihaela Lazaroiu, Maria Soroka-Wojtaszko, Tamás Masszi, Ernst Forjan, Liana Gercheva-Kyuchukova, Franz Bauer, Dorota Krochmalczyk, Árpád Illés, Mikulas Hrubisko, Jolanta Starzak-Gwozdz, Viktor Rossiev
Publikováno v:
The Lancet Haematology. 7:e196-e208
Summary Background The PROUD-PV and CONTINUATION-PV trials aimed to compare the novel monopegylated interferon ropeginterferon alfa-2b with hydroxyurea, the standard therapy for patients with polycythaemia vera, over 3 years of treatment. Methods PRO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef767894c3f5dbd8084e8e09eb738e2f
https://doi.org/10.1016/s2352-3026(19)30236-4
https://doi.org/10.1016/s2352-3026(19)30236-4
Autor:
Elena Karyagina, Sonja Burgstaller, Christoph Klade, Anait L. Melikyan, K D Kaplanov, Tatyana Shneyder, Veronika Buxhofer-Ausch, Christian Schoergenhofer, Slawomira Kyrcz-Krzemien, Juri Hodisch, Atanas Radinoff, Mindaugas Jurgutis, Rolandas Gerbutavičius, Vera Yablokova, Kudrat Abdulkadyrov, Nikolay Tzvetkov, Malgorzata Calbecka, Heinz Gisslinger, Krzysztof Warzocha, Marek Hus, Bernd Jilma, Janusz Kloczko
Publikováno v:
British Journal of Haematology
Summary Anagrelide is an established treatment option for essential thrombocythaemia (ET). A prolonged release formulation was developed with the aim of reducing dosing frequency and improving tolerability, without diminishing efficacy. This multicen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d49e912dd23a885b2aa0fc395c5cd123
https://doi.org/10.1111/bjh.15824
https://doi.org/10.1111/bjh.15824
Autor:
Mervyn Singer, Michael Zörer, Fabio Guarracino, Michael Joannidis, Pavel Dostál, Gianni Biancofiore, Francesca Pratesi, Sebastian Rehberg, Kurt Krejcy, Peter Radermacher, Pavla Kadlecová, Barbara Grohmann-Izay, G. Krumpl, Christian Siebers, Gottfried Heinz, Andrea Morelli, Vladimir Cerny, Olivier Bouvet, Martin Unger, Helmut Trimmel, Massimo Girardis, Christoph Klade
Publikováno v:
Trials, Vol 19, Iss 1, Pp 1-8 (2018)
Trials
Trials
Background In patients with septic shock, the presence of an elevated heart rate (HR) after fluid resuscitation marks a subgroup of patients with a particularly poor prognosis. Several studies have shown that HR control in this population is safe and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0a0e36f7a8d1c52e45d570d3f6733e3
http://link.springer.com/article/10.1186/s13063-018-3024-6
http://link.springer.com/article/10.1186/s13063-018-3024-6
Autor:
Zineb Ghrieb, Stéphane Giraudier, Emmanuelle Verger, Christine Chomienne, Robert Kralovics, Nabih Maslah, Jerome Rey, Barbara Grohmann-Izay, Jean-Jacques Kiladjian, Christoph Klade, Lydia Roy, Bruno Cassinat, Heinz Gisslinger, Juliette Soret-Dulphy
Publikováno v:
Blood Cancer Journal, Vol 8, Iss 10, Pp 1-6 (2018)
Blood Cancer Journal
Blood Cancer Journal
Polycythemia vera is characterized by the acquisition of the JAK2V617F mutation. Recommended treatments include hydroxyurea and interferon-alpha. Several groups have reported a reduction in the JAK2 mutant allele burden in interferon-treated patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31e7bc444428da9543ce4b9aae81a911
http://link.springer.com/article/10.1038/s41408-018-0133-0
http://link.springer.com/article/10.1038/s41408-018-0133-0
Autor:
Johanna Paulsson, Alois Jungbauer, Ralf Sommer, Klaus Hofstädter, Agnes Rodler, Christoph Klade, Romana Zehetner, Peter Satzer
Publikováno v:
Journal of Separation Science
We developed a novel analytical method for concentration determination of tandem single‐chain antibody diphtheria toxin (immunotoxin). The method is based on polymethacrylate monoliths with Protein L ligands as the binding moiety. Different buffers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92cac33a6baedfe0f7cfe8ee94dc1a04
https://doi.org/10.1002/jssc.201800257
https://doi.org/10.1002/jssc.201800257
Autor:
Liana Gercheva-Kyuchukova, Robert Kralovics, Heinz Gisslinger, Miklos Egyed, Árpád Illés, Christoph Klade, Hans Carl Hasselbalch, Lylia Sivcheva, Pencho Georgiev, Kurt Krejcy, Dorota Krochmalczyk, Jiri Mayer, Jean-Jacques Kiladjian, Vera Yablokova, Halyna Pylypenko, Petr Dulíček, Victoria Empson
Publikováno v:
Blood. 138:3660-3660
Introduction: Ropeginterferon alfa-2b (BESREMi®), a novel pegylated interferon with an extended half-life, was approved in Europe for treatment of patients with PV based on results from the phase 3 PROUD-PV and CONTINUATION-PV trials. Ropeginterfero
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61f27031d0f1ebd7cc71d47c1c2313b8
https://doi.org/10.1182/blood-2021-152328
https://doi.org/10.1182/blood-2021-152328